Drugs / HRG2010
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | China (NMPA) | — | 帕金森病 | 2026-08-25 | “国家药品监督管理局下发的《受理通知书》，公司自主研发的2类新药HRG2010胶囊的药品上市申请获受理，适应症为帕金森病。” hengrui.com ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06976346 | Sep → Oct 2021 | Parkinson disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06614153 | May 2023 → Jan 2024 | Parkinson disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06596876 | Nov 2024 → Oct 2025 | Parkinson disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-08-25 | Jiangsu HengRui Medicine Co., Ltd. | Regulatory 恒瑞新药HRG2010胶囊用于帕金森病上市申请获受理 hengrui.com ↗
近日，恒瑞医药收到国家药品监督管理局下发的《受理通知书》，公司自主研发的2类新药HRG2010胶囊的药品上市申请获受理，适应症为帕金森病。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-08-25 | Jiangsu HengRui Medicine Co., Ltd. | 恒瑞新药HRG2010胶囊用于帕金森病上市申请获受理 hengrui.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRG2010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06596876 ↗ |
| Route | Oral | “administered orally” NCT06596876 ↗ |